Salute e Benessere

Veritas Genetic participates in a groundbreaking study highlighting the…

Key Findings of the Study Key Findings of the Study The study, published in the Journal of Personalized Medicine, evaluated women with a family history of breast cancer, demonstrating that PRS significantly improves the accuracy of individual risk prediction. This is particularly relevant for women who are non-carriers of pathogenic variants in susceptibility genes. For carriers of mutations in genes likeBRCA1andBRCA2, PRS offers a complementary approach that helps refine...

XRP Healthcare and Foventa Collaborate for Africa's Premier Lab Expo

This partnership aligns with XRP Healthcare's broader strategy to advance healthcare innovation, particularly in artificial intelligence (AI). The company recently established a dedicated AI team to pioneer advancements in healthcare AI, positioning itself at the forefront of AI integration in diagnostics, patient care, and medical research throughoutAfrica. In conjunction with the event, XRP Healthcare is set to unveil the much-anticipated fourth edition ofXRP Healthcare...

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00…

Saint Herblain (France), October 3, 2024 – Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will host an investor day at the Lotte New York Palace Hotel in New York, NY on Thursday, October 10, 2024 at 10:00 AM ET (4:00 pm CET). The meeting will be conducted in a hybrid way – in person and webcast. To register,click here.The event will focus on Valneva's robust R&D pipeline of potentially first-, only-, or best-in-class vaccine...

IBA and Jules Bordet Institute to lead IHI project Accelerate.EU to create…

A EUR 16 million Initiative to Establish Strategic EU Autonomy in Alpha Therapies for Cancer Louvain-la-Neuve, Belgium , October 3, 2024– IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical production solutions, is pleased to announce that the European Commission has approved the financing of the Accelerate.EU project launching on October 1, 2024. IBA's key role in this new project...

New data indicates use of 3D specimen tomosynthesis can improve breast cancer…

"The MOZART System with its tomosynthesis imaging technology gives us immediate and highly detailed 3D information, which allows us to make more precise surgical decisions," remarked Dr. Kothari. "Reducing repeat surgeries is a huge benefit for patients and healthcare systems." "The MOZART System with its tomosynthesis imaging technology gives us immediate and highly detailed 3D information, which allows us to make more precise surgical decisions," remarked Dr…

Kanazawa University research: Shedding light on how tissues grow with sharply…

Recent advances that have enabled the growth of tissue cultures into organoids and embryoids have heightened interest as to how tissue growth is controlled during the natural processes of embryo development. It is known that the diffusion of signaling molecules called morphogens directs patterned tissue growth but what has been harder to understand is how the gradient of morphogens from this diffusion can lead to sharply defined domains in the resulting tissue (Fig. 1). Now Satoshi Toda at…

Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market…

As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of primary biliary cholangitis in the 7MM were approximately 298K. These cases are projected to increase further during the forecast period (2024–2034). In 2023, the United States had the highest proportion of diagnosed prevalent cases of primary biliary cholangitis among the 7MM, comprising approximately 48% of the total cases. As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of primary…

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 09/30/2024100,093,87388,569,683For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Patricia Sosa Navarro, Chief of Staff to the...

Certara Completes Acquisition of Chemaxon

The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. Chemaxon develops leading scientific informatics software products used by the life sciences industry forin-silicoresearch. Certara develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties of large and small molecules...

Casino Group: Store disposals

Casino Group completes two wavesof store disposalsParis, 2 October 2024Following the agreements reached on 26 May 2023, Casino Group announces that it has sold its controlling 51% stake in 60 stores 1to Groupement les Mousquetaires on 30 September 2024. Groupement les Mousquetaires already holds a 49% stake in these stores from 30 September 2023. *** Following the agreements communicated on 22 June 2024, Casino Group announces the completion yesterday of the acquisition by...

Regenerative Medicine Market to Reach $37.27 Billion by 2031, Driven by the…

Download FREE PDF Brochure Of Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis - https://www.meticulousresearch.com/download-sample-report/cp_id=5864 Download FREE PDF Brochure Of Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis - https://www.meticulousresearch.com/download-sample-report/cp_id=5864 The growth of the regenerative medicine market is driven by the growing number of new regenerative medicine approvals, consistent advancements...

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV…

This collaboration marks a significant step in expanding access to life-saving treatments for heavily treatment-experienced patients with multi-drug-resistant HIV and offers a promising option for HIV prevention in underserved regions. Lenacapavir is a breakthrough HIV-1 capsid inhibitor that works with other antiretroviral drugs to treat multi-drug-resistant HIV-1 infections. It has a unique ability to target multiple stages of the HIV lifecycle, making it highly effective for patients with…

Norgine Announces Appointment of New CEO Janneke van der Kamp

Peter Stein, Chairman of Norgine said: "On behalf of the Norgine Board of Directors and shareholders, we are excited to welcome Janneke to lead Norgine. She is a world class and proven strategic leader with extensive experience in the pharmaceutical industry, leading organisations and launching innovative products to transform patient outcomes. With Janneke's appointment, we have attracted the ideal leader for the next phase of Norgine's exciting growth. Janneke brings to Norgine a deep…

Haier Smart Home Successfully Completes Acquisition of Carrier Commercial…

"We are thrilled to welcome the 4,000+ Carrier Commercial Refrigeration employees into the Haier family," said Li Huagang, Chairman and CEO of Haier Smart Home. "This transaction not only broadens our product portfolio but also provides a unique opportunity to create a better and more sustainable solution provider from industrial & food retail refrigeration to cold storage. The well-known brands such as Carrier Commercial Refrigeration, Profroid, Celsior, and Green &…

Recursion Announces FDA Clearance of Investigational New Drug Application for…

First program to combine Recursion's end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 monthsPlan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphomaSALT LAKE CITY, Oct.02, 2024(GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize...

LenioBio Collaborates with ReciBioPharm to Scale Up ALiCE® Technology and…

This collaboration is part of the expansion in scope of LenioBio's CEPI-funded project, which aims to showcase the capacity and speed of LenioBio's proprietary ALiCE® protein expression technology to accelerate production of vaccine-relevant proteins for use in clinical trials. This project fully aligns with the 100 Days Mission spearheaded by CEPI. This collaboration is part of the expansion in scope of LenioBio's CEPI-funded project, which aims to showcase the capacity and speed of…

10 Clinical Posters Featuring MolecuLight Highlight its Progress Towards…

MolecuLight's showing at SAWC Fall spans a range of clinical applications and highlights new device features. These include optimized wound bed preparation ahead of skin grafting and cellular and tissue-based product (CTP) application, automatic digital wound depth measurement for streamlined workflow, thermal imaging to detect and better treat pressure injuries, associating fluorescence signals with diabetic ulcer healing, and other innovative approaches to wound care. MolecuLight's showing…

Mars unveils the world's largest pet parent study to better understand and serve…

With pet ownership known to be on the rise and people considering pets one of the most important things in their lives, the results signal a new era of pet parent centricity, where the emotional connection between a pet parent and their pet is stronger than ever. With pet ownership known to be on the rise and people considering pets one of the most important things in their lives, the results signal a new era of pet parent centricity, where the emotional connection between a pet parent and...

SyntheticMR Receives Regulatory Approval for SyMRI 15 in Switzerland

SyMRI 15 is a groundbreaking imaging solution that revolutionizes conventional magnetic resonance imaging (MRI) practices. Clinically validated through an extensive multi-center study involving several top-tier institutes in the United States, SyMRI 15 has demonstrated the capability to replace traditional 3D imaging techniques. The study highlighted significant enhancements in efficiency and throughput, without compromising diagnostic accuracy. SyMRI 15 is a groundbreaking imaging solution...

Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companies The appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phaseOculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Daniel S. Char to the role...

Immunovia completes analytical validation of its next-generation pancreatic…

Key highlights of the analytical validation include, Key highlights of the analytical validation include, The analytical validation was conducted using an automated ELISA analyzer, which significantly enhances both performance and throughput compared to Immunovia's prior IMMray platform as well as standard manual ELISA tests. "We are happy to announce that our analytical validation results confirm the strong performance of our next-generation test. This achievement validates the...

Curve Therapeutics further strengthens leadership team with the appointment of…

Curve has also appointed Cora Griffin, an accomplished life sciences business development professional and entrepreneur, as Head of Business Development. Dr Griffin has considerable experience in developing and implementing portfolio strategies from start-ups to large pharmaceutical companies. She was previously Head of Business Development & Alliance Management at ReViral and was instrumental in the acquisition by Pfizer for US$525 million. Cora served as Anti-infectives Strategy Lead at…

LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to…

The Mismatch Repair (MMR) branches of the DNA Damage Repair (DDR) system repair DNA insertions, deletions and misincorporation errors during transcription and/or cellular replication, with two main pathways dependent upon the size of mismatch – MutSα for small mismatches and MutSβ for larger insertion/deletion loops. The Mismatch Repair (MMR) branches of the DNA Damage Repair (DDR) system repair DNA insertions, deletions and misincorporation errors during transcription and/or cellular...

Nexstim Receives NBS System 5 Order from European Customer

Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from an existing customer.Nexstim's NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for non-invasive mapping of the primary motor cortex of the brain. The system provides information that may be used in pre-procedural planning. In addition to the...

Altri Comunicati